Table 1.

Biodistribution of ¹¹¹In-DOTA-Nle-CycMSH_hex in B16/F1 melanoma-bearing C57 mice. The data were presented as percent injected dose/gram or as percent injected dose (Mean±SD, n=5)

Tissues	0.5 h	2 h	4 h	24 h	2 h NDP blockade	2 h L-lysine co-injection
	Percent injected dose/gram (%ID/g)
Tumor	24.94±4.58	19.39±1.65	17.01±2.54	10.53±1.11	0.81±0.03*	14.48±3.25
Brain	0.21±0.07	0.02±0.01	0.06±0.03	0.03±0.01	0.01±0.01	0.04±0.01
Blood	3.33±0.35	0.11±0.07	0.05±0.02	0.02±0.01	0.07±0.05	0.92±0.48
Heart	1.24±0.15	0.16±0.10	0.12±0.03	0.07±0.05	0.06±0.02	0.37±0.02
Lung	2.45±0.83	0.32±0.10	0.10±0.05	0.10±0.03	0.30±0.06	0.75±0.21
Liver	2.75±0.26	1.46±0.20	1.72±0.07	1.89±0.14	1.46±0.08	1.42±0.30
Spleen	1.09±0.33	0.41±0.13	0.47±0.13	0.32±0.08	0.44±0.02	0.43±0.07
Stomach	3.20±0.98	1.25±0.24	1.49±0.12	1.34±0.42	0.36±0.14	1.64±0.78
Kidneys	16.20±4.32	9.52±0.44	9.99±1.39	9.31±0.91	11.56±0.56	6.66±0.62*
Muscle	0.60±0.22	0.15±0.08	0.10±0.08	0.03±0.01	0.02±0.01	0.10±0.08
Pancreas	1.18±0.38	0.14±0.02	0.16±0.02	0.23±0.08	0.12±0.02	0.21±0.05
Bone	1.34±0.40	0.18±0.10	0.22±0.15	0.16±0.03	0.05±0.04	0.55±0.14
Skin	4.11±0.72	0.66±0.23	0.53±0.05	0.64±0.16	0.29±0.02	1.02±0.09
	Percent injected dose (%ID)
Intestines	2.16±0.28	1.40±0.56	3.03±1.06	1.41±0.86	1.14±0.47	1.85±0.73
Urine	57.00±3.91	82.23±5.83	84.61±5.21	87.29±3.60	92.25±1.56	76.79±5.35
	Tumor to normal tissue uptake ratio
Tumor/Blood	7.49	176.27	340.20	526.50	11.57	15.74
Tumor/Kidneys	1.54	2.04	1.70	1.13	0.07	2.17
Tumor/Lung	10.18	60.59	170.10	105.30	2.70	19.31
Tumor/Liver	9.07	13.28	9.89	5.57	0.55	10.20
Tumor/Muscle	41.57	129.27	170.10	351.00	40.50	144.80
Tumor/Skin	6.07	29.38	32.09	16.45	2.79	14.20

^*P <0.05, significance comparison between the tumor uptakes of ¹¹¹In-DOTA-Nle-CycMSH_hex with or without NDP-MSH blockade, and between the kidney uptakes of ¹¹¹In-DOTA-Nle-CycMSH_hex with or without L-lysine co-injection.